Skip to main content

Amphetamine Extended-Release

Generic: Amphetamine Extended-Release

Data may be stale·Apr 23, 2026
Manufacturer
Takeda
NDC
62542-005
RxCUI
1739803
Route
ORAL
ICD-10 indication
F90.9

Affordability Check

How much will you actually pay for Amphetamine Extended-Release?

In 30 seconds, see every legitimate way to afford Amphetamine Extended-Release — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Amphetamine Extended-Release

Adderall XR is a central nervous system stimulant medication primarily prescribed for the treatment of attention deficit hyperactivity disorder (ADHD). It functions by affecting certain chemicals in the brain and nerves that contribute to hyperactivity and impulse control. By balancing these substances, the medication helps patients increase their focus, stay on task, and manage behavioral problems. This extended-release formulation is engineered to enter the bloodstream gradually throughout the day, providing a steady therapeutic effect and reducing the need for multiple doses.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Amphetamine Extended-Release appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

2%

102 of 5,499 plans

Most common tier

Tier 4

On 65% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)7
35%
Tier 4 (non-preferred brand)13
65%

Step therapy: 0% of formularies

Quantity limits: 0% of formularies

Coverage breadth: 20 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.